Highest-materiality recent filing
Rallybio to merge with Avenzo Therapeutics; pre-merger Avenzo holders to own ~56.6% of combined co
Avenzo stockholders expected to own ~56.6% of combined co; Rallybio stockholders ~2.8%; new investors in $215M concurrent financing ~40.6% on fully diluted basis.
Rallybio receives $50M termination fee after Candid merger terminates for UCB deal
Candid Therapeutics terminated its merger with Rallybio to enter a Permitted Alternative Agreement with UCB S.A.
Rallybio CMO Steven Ryder departs immediately; severance tied to pending Candid merger
Steven Ryder, M.D., Chief Medical Officer, leaves Rallybio effective March 31, 2026.
Rallybio agrees to reverse merger with Candid; Rallybio holders get ~3.65% of combined firm
Rallybio pre-merger holders expected to own ~3.65% of combined company; Candid holders ~57.55%; financing investors ~38.80% (based on $505.5M raise).
Rallybio announces 1-for-8 reverse stock split effective Feb 6, 2026
Reverse stock split at 1-for-8 ratio approved by shareholders; effective 12:01 a.m. ET on Feb 6, 2026.
Rallybio posts Q3 net income of $16.0M on $20M REV102 sale; RLYB116 data expected Q4 2025
Revenue $0.2M vs $0.3M YoY; R&D expenses fell to $4.1M (from $8.2M); G&A $3.0M (from $4.1M).
Rallybio fails Nasdaq bid price compliance; transfer to Capital Market grants extension to Feb 2026
Nasdaq notified Rallybio on Aug 26, 2025 of transfer to Capital Market; stock continues trading as RLYB.
Rallybio Q2 net loss $9.7M, sells REV102 to Recursion for $25M; RLYB116 data Q3/Q4 2025
Net loss of $9.7M ($0.22/share) vs $16.2M in Q2 2024; revenue $0.2M.
Rallybio sells ENPP1 JV stake to Recursion for up to $25M; cash runway to mid-2027
Upfront equity payment of $7.5M (1,457,952 Recursion shares); potential $12.5M contingent equity and $5M clinical milestone.
Rallybio Q1 net loss $9.4M; discontinues RLYB212, cuts workforce 40%
Net loss $9.4M ($0.21 per share) vs $19.0M ($0.47) in Q1 2024; revenue $0.2M from J&J collaboration.
Rallybio discontinues RLYB212 for FNAIT after Phase 2 PK misses efficacy targets
Phase 2 PK results: RLYB212 concentrations near/ below assay LLoQ, missing minimum target of 3 ng/mL and predicted 6-10 ng/mL.
Rallybio Q4 net loss $11M, cash $65.5M; key trial data readouts in 2025
Q4 2024 net loss $11.0M ($0.25/share) vs $20.2M ($0.50/share) in Q4 2023; full-year loss $57.8M.
Rallybio receives Nasdaq bid price deficiency notice; faces potential delisting
Notice on Feb 24, 2025: closing bid price below $1.00 for 30 consecutive business days.
Rallybio Q3 net loss narrows to $11.5M; RLYB212 Phase 2 to screen in Q4
Net loss $11.5M ($0.26/share) vs $18.4M ($0.45) in Q3 2023; revenue $0.3M from J&J collaboration.
Rallybio Q2 net loss $16.2M; cash $88.6M; RLYB212 Phase 2 on track for Q4 2024
Q2 net loss $16.2M ($0.37/share) vs $18.6M ($0.46/share) in Q2 2023.
Rallybio posts Q1 net loss of $19.0M; cash $94.2M; on track for RLYB212 Phase 2 in 2H 2024
Net loss of $19.0M ($0.47 per share) vs $17.3M ($0.43 per share) in Q1 2023.
Rallybio announces J&J collaboration with $0.5M upfront and $6.6M equity for FNAIT
Collaboration with J&J: Rallybio receives $0.5M upfront, up to $3.7M milestones for FNAIT data sharing and awareness.
On September 16, 2024, Dr. Kush Parmar informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he intends to resign as a member of the Board and as Chair of the Nominating and Corporate Governance Committee of the Board effective October 31, 2024.
On July 23, 2024, Martin Mackay, Ph.D., informed the Board of Directors (the Board) of Rallybio Corporation (Rallybio) that he will resign his Executive Chairman role and his employment with Rallybio, effective December 31, 2024.
Max materiality 0.90 · Median 0.60 · Most common event earnings